241 related articles for article (PubMed ID: 29127619)
1. Changes in the lung bacteriome in relation to antipseudomonal therapy in children with cystic fibrosis.
Kramná L; Dřevínek P; Lin J; Kulich M; Cinek O
Folia Microbiol (Praha); 2018 Mar; 63(2):237-248. PubMed ID: 29127619
[TBL] [Abstract][Full Text] [Related]
2. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.
Heirali AA; Workentine ML; Acosta N; Poonja A; Storey DG; Somayaji R; Rabin HR; Whelan FJ; Surette MG; Parkins MD
Microbiome; 2017 May; 5(1):51. PubMed ID: 28476135
[TBL] [Abstract][Full Text] [Related]
3. Strong incidence of Pseudomonas aeruginosa on bacterial rrs and ITS genetic structures of cystic fibrosis sputa.
Pages-Monteiro L; Marti R; Commun C; Alliot N; Bardel C; Meugnier H; Perouse-de-Montclos M; Reix P; Durieu I; Durupt S; Vandenesch F; Freney J; Cournoyer B; Doleans-Jordheim A
PLoS One; 2017; 12(3):e0173022. PubMed ID: 28282386
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis.
Reid DW; Latham R; Lamont IL; Camara M; Roddam LF
J Cyst Fibros; 2013 Dec; 12(6):688-99. PubMed ID: 23706827
[TBL] [Abstract][Full Text] [Related]
5. Comparison of conventional and molecular methods for the detection of bacterial pathogens in sputum samples from cystic fibrosis patients.
van Belkum A; Renders NH; Smith S; Overbeek SE; Verbrugh HA
FEMS Immunol Med Microbiol; 2000 Jan; 27(1):51-7. PubMed ID: 10617790
[TBL] [Abstract][Full Text] [Related]
6. Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum.
Baxter CG; Rautemaa R; Jones AM; Webb AK; Bull M; Mahenthiralingam E; Denning DW
Thorax; 2013 Jul; 68(7):652-7. PubMed ID: 23513028
[TBL] [Abstract][Full Text] [Related]
7. The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome.
Heirali AA; Acosta N; Storey DG; Workentine ML; Somayaji R; Laforest-Lapointe I; Leung W; Quon BS; Berthiaume Y; Rabin HR; Waddell BJ; Rossi L; Surette MG; Parkins MD
J Cyst Fibros; 2019 Nov; 18(6):829-837. PubMed ID: 30857926
[TBL] [Abstract][Full Text] [Related]
8. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa populations in the cystic fibrosis lung lose susceptibility to newly applied β-lactams within 3 days.
Tueffers L; Barbosa C; Bobis I; Schubert S; Höppner M; Rühlemann M; Franke A; Rosenstiel P; Friedrichs A; Krenz-Weinreich A; Fickenscher H; Bewig B; Schreiber S; Schulenburg H
J Antimicrob Chemother; 2019 Oct; 74(10):2916-2925. PubMed ID: 31355848
[TBL] [Abstract][Full Text] [Related]
10. Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium.
Collie D; Glendinning L; Govan J; Wright S; Thornton E; Tennant P; Doherty C; McLachlan G
PLoS One; 2015; 10(11):e0142097. PubMed ID: 26544950
[TBL] [Abstract][Full Text] [Related]
11. Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention.
Cuthbertson L; Rogers GB; Walker AW; Oliver A; Green LE; Daniels TW; Carroll MP; Parkhill J; Bruce KD; van der Gast CJ
ISME J; 2016 May; 10(5):1081-91. PubMed ID: 26555248
[TBL] [Abstract][Full Text] [Related]
12. Loss of bacterial diversity during antibiotic treatment of intubated patients colonized with Pseudomonas aeruginosa.
Flanagan JL; Brodie EL; Weng L; Lynch SV; Garcia O; Brown R; Hugenholtz P; DeSantis TZ; Andersen GL; Wiener-Kronish JP; Bristow J
J Clin Microbiol; 2007 Jun; 45(6):1954-62. PubMed ID: 17409203
[TBL] [Abstract][Full Text] [Related]
13. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
14. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
[TBL] [Abstract][Full Text] [Related]
15. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation.
Ciofu O; Riis B; Pressler T; Poulsen HE; Høiby N
Antimicrob Agents Chemother; 2005 Jun; 49(6):2276-82. PubMed ID: 15917521
[TBL] [Abstract][Full Text] [Related]
16. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
[TBL] [Abstract][Full Text] [Related]
17. Different next generation sequencing platforms produce different microbial profiles and diversity in cystic fibrosis sputum.
Hahn A; Sanyal A; Perez GF; Colberg-Poley AM; Campos J; Rose MC; Pérez-Losada M
J Microbiol Methods; 2016 Nov; 130():95-99. PubMed ID: 27609714
[TBL] [Abstract][Full Text] [Related]
18. Divergence of bacterial communities in the lower airways of CF patients in early childhood.
O'Connor JB; Mottlowitz MM; Wagner BD; Boyne KL; Stevens MJ; Robertson CE; Harris JK; Laguna TA
PLoS One; 2021; 16(10):e0257838. PubMed ID: 34613995
[TBL] [Abstract][Full Text] [Related]
19. Molecular typing of the bacterial flora in sputum of cystic fibrosis patients.
Kolak M; Karpati F; Monstein HJ; Jonasson J
Int J Med Microbiol; 2003 Aug; 293(4):309-17. PubMed ID: 14503795
[TBL] [Abstract][Full Text] [Related]
20. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
